Interpace Biosciences (IDXG)
(Delayed Data from OTC)
$1.47 USD
+0.05 (3.16%)
Updated Jun 7, 2024 03:03 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
IDXG 1.47 +0.05(3.16%)
Will IDXG be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for IDXG based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for IDXG
TherapeuticsMD (TXMD) Reports Q3 Loss, Lags Revenue Estimates
Organon (OGN) Q3 Earnings and Revenues Top Estimates
IDXG: What are Zacks experts saying now?
Zacks Private Portfolio Services
UpHealth, Inc. (UPH) Reports Q2 Loss, Lags Revenue Estimates
CareDx (CDNA) Reports Q2 Loss, Lags Revenue Estimates
XpresSpa Group, Inc. (XSPA) Reports Q1 Loss, Tops Revenue Estimates
Other News for IDXG
Interpace Diagnostics Announces New Data Analyzing Imbalance of Short Tandem Repeat Alleles for Pancreatic Cancer Detection Published as an ASCO 2024 Abstract
Interpace Biosciences Announces First Quarter 2024 Financial and Business Results
Interpace Biosciences GAAP EPS of -$0.11
Interpace Biosciences announces preliminary Q4 revenue of $10.3M
Interpace Biosciences Announces Preliminary Full-year and Fourth Quarter 2023 Financial and Business Results